Discovery of SMD-3040 as a Potent and Selective Degrader for the Synthetic Lethality Target, SMARCA2

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2023; 19(11): 1151
DOI: 10.1055/s-0042-1751596

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Seong Heon Kim (Hyundai Pharm)

SMARCA2 - SMARCA4 - anticancer - PROTAC degrader - synthetic lethality - SMD 3040 - lead

Article published online:
14 October 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany